Available online at www.sciencedirect.com
ScienceDirect
Tetrahedron Letters 49 (2008) 2320–2323
Tetrahedron Letters

Convenient preparation of *N*-8-quinolinyl benzenesultams as novel NF-κB inhibitors

Yuli Xie [a], Gangli Gong [a], Yidong Liu [a], Shixian Deng [a], Alison Rinderspacher [a], Lars Branden [b], Donald W. Landry [a,*]

[a] *Department of Medicine, Columbia University, 630 W 168th Street, New York, NY 10032, USA*
[b] *Department of Physiology and Cellular Biophysics, Russ Berrie Med Sc Pav 1150 St Nicholas Ave 520, New York, NY 10032, USA*

Received 5 September 2007; revised 28 January 2008; accepted 30 January 2008
Available online 6 February 2008

Abstract

An efficient synthesis of a series of *N*-8-quinolinyl benzenesultams as novel NF-κB inhibitors was described via diazotization-induced cyclization of easily accessible *N*-8-quinolinyl-2-aminobenzenesulfonamides.

Keywords: Benzenesultam; NF-κB; Diazotization; Cyclization

Nuclear factor kappaB (NF-κB) is a pivotal transcription factor that regulates gene expression involved in inflammation and immune responses. The NF-κB pathway has provided a favorable target for pharmacological intervention of chronic inflammation, neurodegenerative diseases, and certain types of cancer, where the pathway is often constitutively or excessively active. Peptides, siRNA, natural products, and small molecules that target one or multiple steps of NF-κB signaling are under investigation as potential therapeutics.[2] Our NIH Molecular Libraries Screening Centers Network (MLSCN) recently identified sultam **1** (Fig. 1) as a novel NF-κB inhibitor in cell-based high throughput screening assays.

NF-κB is normally sequestered in the cytoplasm through an association with its inhibitory protein IκB. Upon stimulation of the NF-κB pathway, IκB is rapidly phosphorylated, ubiqutinated, and then degraded by proteasomes. Freed from its inhibition, NF-κB translocates to the nucleus where it binds to DNA regulatory sites and activates specific gene expression.[1] Preliminary results[3] show that compound **1** stabilizes IκB and prevents NF-κB translocation in different types of cells with sub-micromolar IC_{50}s. In contrast to existing blockers of NF-κB translocation, compound **1** did not appear to inhibit IκB kinases (IKKs) and proteasomes, the major components of the IκB degradation machinery, and thus likely represents a structurally and pharmacologically new class of modulators of the NF-κB pathway. For structure–activity relationship studies and further biological investigation, we sought an easy synthetic access to the original hit **1** and its analogs.



1

Fig. 1. The structure of NF-κB inhibitor **1**.

The tetracyclic target **1** consists of a structurally constrained cyclic sulfonamide with the sultam bridging quinolinyl and phenyl moieties. This unique scaffold has rarely been studied and lacks a general synthetic method. In this Letter, we describe an efficient synthesis of this class of compounds that allows a diverse substitution pattern.

* Corresponding author. Tel.: +1 212 3055839; fax: +1 212 3053475.
E-mail address: dwl1@columbia.edu (D. W. Landry).

0040-4039/$ - see front matter © 2008 Elsevier Ltd. All rights reserved.
doi:10.1016/j.tetlet.2008.01.136



Scheme 1. The attempts of intermolecular arylation.

Our synthetic strategy was to construct the sultam skeleton through the cyclization of easily accessible *N*-8-quinolinyl benzenesulfonamides. We first attempted metal-mediated intermolecular arylation. As shown in Scheme 1, 8-aminoquinoline **2** was treated with 2-bromobenzenesulfonyl chloride in pyridine followed by the protection of the nitrogen on sulfonamide with Boc_2O to give precursor **3**. Unfortunately, palladium-catalyzed direct intramolecular arylation[4] of bromide **3** failed to effect cyclization. Bromination of 8-aminoquinoline **2** provided dibromide,[5] and subsequent sulfonamidation yielded tribromide **6**. However, neither Ullmann reaction nor palladium-catalyzed intramolecular coupling[6] of aryl bromide **6** afforded the desired product **7**.

Ultimately, diazotization-induced cyclization was employed to synthesize the target compound (Scheme 2). Sulfonamide **8** was prepared, as above, from 2-nitrobenzenesulfonyl chloride and 8-aminoquinoline **2** in pyridine. The nitro group was reduced with $SnCl_2$ to provide amine **9**, and subsequent diazotization afforded triazine **10** in good yield. A literature procedure employing Cu(0) and NaOH[7] failed to yield the desired product, but we found that thermolysis in a variety of solvents (EtOH, H_2O, DMSO, or HOAc) or neat afforded product **1** in moderately poor yield. The best result (41% yield) was obtained by heating in glacial acetic acid at 120 °C for 10 min. Beyond low yield, thermolysis in acid generated large amounts of intractable tar and required multiple rounds of chromatography on silica gel.

In the course of improving the synthesis of the triazine intermediates, we attempted a mild non-aqueous diazotization-induced by *tert*-butyl nitrite (*t*-BuONO). This led to our discovery of a convenient one-pot synthesis of *N*-8-quinolinyl benzenesultams from *N*-8-quinolinyl-2-aminobenzenesulfonamides. In a typical reaction, as shown in Scheme 3, 2-aminobenzenesulfonamide **9a** prepared from 6-methoxy-2-methylquinolin-8-amine **2a**[8] was dissolved in HOAc and treated with 1.5 equiv of *t*-BuONO at 10 °C. The reaction was allowed to warm to room temperature over 10 min and smoothly afforded sultam **1a** in good yield (78%) without the isolation of the triazine intermediate.[9]

To investigate the scope of this one-pot protocol, a selection of *N*-8-quinolinyl-2-aminobenzenesulfonamides (**9a**–**p**) was prepared and subsequently cyclized in one-pot reactions to give sultams (**1a**–**p**). In each case, the



Scheme 2. Synthesis of sultam **1** via triazine intermediate.



Scheme 3. The one-pot synthesis of compound **1a**.

Table 1
The one-pot synthesis of *N*-8-quinolinyl benzenesultams



Comp	R^1	R^2	R^3	R^4	R^5	R^6	R^7	R^8	R^9	Yield (%)
1a	CH_3	H	H	H	OCH_3	H	CH_3	H	H	78
1b	H	H	H	H	H	H	OCH_3	H	H	76
1c	H	H	H	H	H	H	CF_3	H	H	81
1d	H	H	H	H	H	H	Cl	H	H	79
1e	H	H	H	H	H	H	CH_3	H	H	95
1f	CH_3	H	H	H	H	H	F	H	H	75
1g	CH_3	H	H	H	H	H	OCH_3	H	H	70
1h	CH_3	H	H	H	H	H	CF_3	H	H	91
1i	CH_3	H	H	H	H	H	H	H	H	90
1j	H	CH_3	H	H	H	H	H	H	H	77
1k	H	H	CH_3	H	H	H	H	H	H	79
1l	H	H	H	Cl	H	H	H	H	H	73
1m	H	H	H	H	H	H	F	H	H	84
1n	H	H	H	H	H	H	H	Cl	H	80
1o	H	H	H	H	H	H	H	CH_3	H	72
1p	H	H	H	H	H	H	H	H	Cl	75



Scheme 4. Synthesis of quinazolines of **9i–k** by Skraup reaction.

product was isolated in good yield without tedious purification (Table 1). Aminobenzenesulfonamides (**9b–h** and **9l–p**) were synthesized in a similar manner described in Scheme 3. Intermediates **9i–k** were prepared from aniline **11** as outlined in Scheme 4: Sulfonamidation of aniline **11** with 2-nitrobenzenesulfonyl chloride provided sulfonamide **12**. Skraup reaction under modified conditions[10] followed by the reduction of nitro group readily afforded the *N*-quinolinyl sulfonamides (**9i–k**).

In summary, a highly efficient one-pot reaction for the conversion of *N*-8-quinolinyl-2-aminobenzenesulfonamides into their corresponding sultams under very mild conditions has been described. This procedure offered a convenient access to a unique class of heterocyclic compounds that have shown therapeutic potential as novel NF-κB inhibitors. Its potential as a general method to prepare other biologically interesting biaryls is under investigation.

References and notes

1. Hayden, M. S.; West, A. P.; Ghosh, S. *Oncogene* **2006**, *25*, 6758.
2. Gilmore, T. D.; Herscovitch, M. *Oncogene* **2006**, *25*, 6887.
3. Unpublished data from Columbia and NCGC MLSCN Center.
4. Campeau, L. C.; Parisien, M.; Jean, A.; Fagnou, K. *J. Am. Chem. Soc.* **2006**, *128*, 581.
5. Bagheri, M.; Azizi, N.; Saidi, M. *Can. J. Chem.* **2005**, *83*, 146.
6. Wang, L.; Zhang, Y.; Liu, L.; Wang, Y. *J. Org. Chem.* **2006**, *71*, 1284.
7. Ullmann, F.; Gross, C. *Ber. Dtsch. Chem. Ges.* **1911**, *43*, 2694.
8. Qiu, L.; Jiang, P.; He, W.; Tu, C.; Lin, J.; Li, Y.; Gao, X.; Gu, Z. *Inorg. Chim. Acta* **2007**, *360*, 431.
9. *A typical synthesis*: Compound **9a**: To a solution of 6-methoxy-2-methylquinolin-8-amine **2a** (0.19 g, 1.0 mmol) in pyridine (5 ml) was

added 4-methyl-2-nitrobenzenesulfonyl chloride (0.24 g, 1.0 mmol). The mixture was stirred at room temperature overnight and precipitated with H_2O. The crude product was filtered and recrystallized from EtOH to afford nitrobenzenesulfonamide (0.31 g, 79%) as red crystal. ^{1}H NMR (300 MHz, $CDCl_3$) δ 10.1 (br, 1H); 8.04 (d, 1H), 7.86 (d, 1H), 7.62 (m, 2H), 7.39 (d, 1H), 7.24 (d, 1H), 6.73 (s, 1H), 3.88 (s, 3H), 2.66 (s, 3H), 2.41 (s, 3H); ESI-MS (M^++1): 388.0. To a suspension of above nitro compound (0.20 g, 0.56 mmol) in EtOH (5 ml) $SnCl_2$ (0.32 g, 1.7 mmol) was slowly added. The mixture was refluxed for 2 h. After the removal of EtOH, the residue was treated with 1 M NaOH. The aqueous solution was extracted with CH_2Cl_2. The combined organic phases were washed by brine, dried over Na_2SO_4, and concentrated to yield **9a** (0.18 g, 92%) as a white solid. ^{1}H NMR (300 MHz, $CDCl_3$) δ 9.42 (br, 1H); 7.83 (d, 1H), 7.65 (d, 1H), 7.30 (s, 1H), 7.23 (d, 1H), 6.64 (s, 1H), 6.48 (d, 1H), 6.42 (s, 1H), 3.80 (s, 3H), 2.61 (s, 3H), 2.17 (s, 3H); ESI-MS (M^++1): 358.1. Compound **1a**: To a solution of **9a** (0.1 g, 0.28 mmol) in HOAc (1 ml) at 10 °C was added *t*-BuONO (0.05 ml, 0.42 mmol). The reaction was slowly warmed to room temperature over 10 min and quenched with H_2O. The mixture was extracted with EtOAc. The combined organic phases were washed with saturated $NaHCO_3$, dried over Na_2SO_4, and concentrated. Flash chromatography (EtOAc/CH_2Cl_2 1:10 v/v) gave **1a** (74 mg, 78%) as a yellow solid. ^{1}H NMR (300 MHz, $CDCl_3$) δ 8.49 (s, 1H), 7.98 (d, 1H), 7.92 (d, 1H), 7.37 (d, 1H), 7.25 (d, 1H), 6.87 (s, 1H), 4.00 (s, 3H), 2.69 (s, 3H), 2.52 (s, 3H); ^{13}C NMR (75 MHz, $CDCl_3$) δ 156.2, 155.2, 142.2, 134.8, 134.5, 134.1, 132.2, 131.4, 130.1, 129.0, 126.8, 124.4, 122.0, 112.5, 100.0, 56.2, 25.2, 22.6; ESI-MS (M^++1): 341.2.

10. Matsugi, M.; Tabusa, F.; Minamikawa, J. *Tetrahedron Lett.* **2000**, *41*, 8523.